Skip to main content

Table 3 Selected ongoing immunotherapy-based clinical trials

From: Mechanisms of immune evasion in breast cancer

Patient population Regimen Phase NIH No
HER2-negative advanced breast cancer STEMVAC I NCT02157051
HER2-negative advanced breast cancer WOKVAC I NCT02780401
HER2- negative metastatic breast cancer with BRCA1 or BRCA2 mutation MEDI4736 with Olaparib I/II NCT02734004
HER2-negative metastatic breast cancer MEDI4736 with Tremelimumab II NCT02536794
HER2-negative metastatic breast cancer Pembrolizumab+Aromatase Inhibitor II NCT02648477
HER2-negative metastatic breast cancer Pembrolizumab and Nab-paclitaxel II NCT02752685
Recurrent HER2-negative metastatic breast cancer Opdivo & Abraxane I NCT02309177
Advanced triple negative breast cancer Pembrolizumab plus chemotherapy I/II NCT02331251
Advanced triple negative breast cancer AM0010 (recombinant human IL-10) I NCT02009449
Advanced triple negative breast cancer MEDI4736 with Olaparib or Cediranib I/II NCT02484404
Advanced triple negative breast cancer MEDI4736 with Vigil II/III NCT02725489
Advanced triple negative breast cancer PVX-410 Vaccine in combination with Durvalumab I NCT02826434
Advanced triple negative breast cancer Entinostat and Nivolumab with or without Ipilimumab I NCT02453620
Advanced triple negative breast cancer Tremelimumab II NCT02527434
Advanced triple negative breast cancer Atezolizumab+Nab-Paclitaxel II NCT02425891
Advanced triple negative breast cancer PDR001 I/II NCT02404441
Metastatic triple-negative breast cancer Pembrolizumab plus chemotherapy I/II NCT02734290
Metastatic triple-negative breast cancer Halaven & Pembrolizumab I/II NCT02513472
Metastatic triple-negative breast cancer Pembrolizumab with Carboplatin and Gemcitabine II NCT02755272
Metastatic triple-negative breast cancer Pembrolizumab plus radiotherapy II NCT02730130
Metastatic triple-negative breast cancer TAK-659 with Nivolumab I NCT02834247
Metastatic triple-negative breast cancer CSF1R Inhibitor (PLX3397) with Pembrolizumab I/II NCT02452424
Metastatic triple-negative breast cancer Single-dose Cyclophosphamide +Pembrolizumab II NCT02768701
Metastatic triple-negative breast cancer Pembrolizumab I NCT02447003
Metastatic triple-negative breast cancer Pembrolizumab III NCT02555657
Metastatic triple-negative breast cancer Niraparib with Pembrolizumab I/II NCT02657889
Stage I-III triple negative breast cancer MEDI4736 and chemotherapy before surgery I/II NCT02489448
HER2+ breast cancer NeuVax with Herceptin II NCT01570036
HER2+ breast cancer Atezolizumab with Trastuzumab Emtansine or with Trastuzumab and Pertuzumab I NCT02605915
HER2+ advanced breast cancer AdHER2/neu dendritic cell vaccine I NCT01730118
ER+, stage I, II or III breast cancer MONTANIDE™ ISA 51 VG combined with neoadjuvant chemotherapy I/II NCT02229084
Metastatic breast cancer Hypofractionated radiotherapy with MEDI4736 and Tremelimumab I NCT02639026
Persistent Triple-Negative Disease Personalized polyepitope DNA vaccine following neoadjuvant chemotherapy I NCT02348320
  1. Note: STEMVAC, WOKVAC, Vigil, NeuVax, MONTANIDE™ ISA 51 VG (vaccines); MEDI4736, Atezolizumab (anti-PD-L1), Olaparib, Niraparib (PARP inhibitor); Tremelimumab, Ipilimumab (anti-CTLA-4); Pembrolizumab; Nivolumab, PDR001 (anti-PD-1); Entinostat (HDACi); TAK-659 (SYKi). Data extracted from https://www.breastcancertrials.org